Vessl Prosthetics at RESI

1 Dec

By Rikki Piccirillo, Marketing Manager, LSN

RikkiCo-Founders, Sydney Robinson and Oleksiy Zaika of Vessl Prosthetics joined us at RESI Boston in September. With an understanding of the value of building relationships early in their fundraising journey, attending RESI made perfect sense. This team made the most of their time at RESI, researching attending investors, strategizing panel attendance, and capitalizing on every learning and networking opportunity that presented itself. As thorough and prepared as they were for their time at RESI, the same zest can be said for how Vessl Prosthetics came to be. In this interview with Sydney, you can learn more about their company, the product their developing and their strategy at RESI:

Registration is open for RESI JPM San Francisco, January 10 In Person at the Marines’ Memorial Club & Hotel & January 11-12 online Virtual Partnering.


RESI JPM San Francisco Sponsor Highlight – Husch Blackwell

1 Dec

By Antoinette Lowre, Manager of Business Development, LSN

Life Science Nation was thrilled to have Hush Blackwell at RESI Boston in September as a Silver Sponsor. Their sponsorship included a workshop, Leveraging IP for Growing an Investable Medtech Company, hosted by Hush Blackwell Partner, Bryan Stewart. This panel highlighted the importance of IP leverage and included testimonials and insight from some of their current clients. Bryan stated:

“The Husch Blackwell team had a great experience sponsoring the RESI Boston conference. We featured founders from funded companies restor3d, Trio Labs, and protect3d on our panel presentation titled ‘Leveraging IP for Growing an Investable MedTech Company.’ Our team and our panelists enjoyed the industry-relevant RESI presentations, the pitch competitions, and networking with others in the RESI and LSN ecosystem. We found sponsoring RESI Boston immensely valuable – we will be back sponsoring RESI JPM!”

Husch Blackwell will be at RESI JPM in San Francisco as a Gold Sponsor and will be hosting another panel during our packed 1-day in person event on January 10, followed by two virtual partnering days.

To learn more about sponsorship and the benefits of sponsoring at RESI JPM, check out our Sponsorship Brochure and reach out to with any questions or to book a meeting with your business development rep.


Join Us as a Media Partner in 2023

1 Dec

By Caitlin Dolegowski, Marketing Manager, LSN

Calling all life science industry media producers: partner with us in promoting Life Science Nation (LSN)’s RESI conference series in 2023, and get valuable discounts for the members of your ecosystem!

LSN’s partnering conference series is the biggest in North America focusing on early-stage life science investments and strategic partnerships. At each conference event, we expect between 700-1,200 attendees participating from 5 continents.

Media partnership isn’t just a promotional tool for publicity and customer loyalty, it can also be expected to generate good will and awareness at LSN’s conference series. LSN makes media sponsorship as convenient as possible. As a media sponsor, you would promote and advertise LSN partnering conferences through your communication channels, and in return, LSN offers including:

  • Your logo on LSN’s Next Phase Newsletter (45,000+ readership), event websites, and program guide.
  • A unique discount for your subscribers for RESI conferences.
  • Our media partners receive a complimentary ticket and additional free tickets for every two registrations you provide.

For additional exposure we offer two posts of our LinkedIn network and a banner ad featured in our newsletter during 2023.

For more information, please contact Caitlin Dolegowski, Marketing Manager, LSN


Hot Investor Mandate: VC Firm Invests in USA-Based Medical Device & Diagnostics Companies With Established Proof of Concept and Working Prototype

1 Dec

A Venture Capital firm based in USA is currently investing out of their fourth fund. The firm looks to make early-stage investments, typically in Series A companies. Investments range from $1M to $1.5M in the initial round with up to $3M in reserve for follow on financings. The firm invests across the United States. The firm prefers to syndicate rounds with additional strong institutional investors, and is willing to serve as lead investor.

The firm invests solely in early-stage medical device and diagnostics companies. The firm generally looks for companies that have created an early working prototype or obtained a proof-of-concept with supporting data.

The firm seeks privately-held companies and maintains positive and productive working relationships with its portfolio companies, providing proactive assistance. The firm is more open to taking significant scientific and technical risk as opposed to sales and marketing challenges, preferring its investment to fund clinical trials and regulatory approval.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Global VC Invests in Therapeutics and Medical Technologies With Strong Interest in Oncology, Immunology, and Rare Diseases

1 Dec

A global venture capital and commercial development firm based in the USA has raised five life science-focused venture funds its flagship Venture Capital business unit and is currently investing out of its fifth fund. In addition, the firm recently closed on a new fund that is investing in companies domiciled in Singapore, Hong Kong and China. The firm generally looks to support companies with lead assets that can reach high value inflection points in 3-4 years and will consider opportunities in US, Canada, Europe, Singapore, Hong Kong and China.

The firm is currently seeking companies developing therapeutics or medical technologies to treat true unmet medical needs. The firm is therapeutic area agnostic, although the firm has historically been most active in immunology, oncology, and rare diseases. The firm typically prefers to invest in Series A/B rounds with a preference for lead assets between 18 months pre-IND and Phase 2a. Within devices, the firm generally prefers to invest in later stage opportunities, particularly those devices that have received market approval with early revenue.

The firm does not have any specific requirements for a firm’s management team. The firm is an active investor and seeks a director or observer position on a company’s board.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Seed Fund Actively Seeks Opportunities in Software-Based Healthcare Companies, Including Digital Health, Diagnostics, R&D Services

1 Dec

A seed fund focuses on applied AI technologies, and invests in three verticals: Digital Health, Enterprise and Automation. Within Digital Health, the firm invests in companies developing AI/ML, software-based technologies in the sectors of digital health, diagnostics and R&D services. The firm will invest $250K-500K in seed-stage companies based in the US and Canada, and will consider all companies, as long as they have a good business model.

Within healthcare, the firm invests in companies that are primarily software-based. In addition to digital health companies, the firm will consider diagnostics and R&D services companies, such as smart lab monitoring, genomics-based diagnostics, or AI-driven drug discovery.

The firm will invest only in companies whose primary base of operations is in the US and Canada, and with those focused on the US/Canadian market. While the firm may take a board or observer seat after investing, they do not require it for all of their investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Multi-Family Office Backed Venture Fund Invests in Medical Technology and Lab Equipment, With Strong Interest In Western USA-Based Companies

1 Dec

A multi-family venture fund based in the US is an active investor in the medical device sector, and is interested in opportunities in the western United States. Initial investments are typically about $150,000 with the potential for follow-on investments totaling $1 million and may be structured as equity or as debt. In the recent past, the firm has allocated new investments at a rate of approximately one every two months. The firm offers support and expertise to portfolio companies but does not seek a board seat.

The firm is interested in medical technology and lab equipment, including electro-mechanical medical devices, active implantable devices, and surgical instruments. The firm invests only in companies that have already developed a prototype of their product,  filed a patent application and have animal data.

The firm seeks to invest in strong management teams with prior experience in the medical device industry. The firm prefers to make investments with the potential to exit within 3-4 years.

If you are interested in more information about this investor and other investors tracked by LSN, please email

%d bloggers like this: